These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36809193)

  • 1. A multicenter, randomized, placebo-controlled study to select the minimum effective dose of estetrol in postmenopausal participants (E4Relief): part 2-vaginal cytology, genitourinary syndrome of menopause, and health-related quality of life.
    Gaspard U; Taziaux M; Jost M; Coelingh Bennink HJT; Utian WH; Lobo RA; Foidart JM
    Menopause; 2023 May; 30(5):480-489. PubMed ID: 36809193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Randomized, Multicenter, Double-Blind, Study to Evaluate the Safety and Efficacy of Estradiol Vaginal Cream 0.003% in Postmenopausal Women with Vaginal Dryness as the Most Bothersome Symptom.
    Archer DF; Kimble TD; Lin FDY; Battucci S; Sniukiene V; Liu JH
    J Womens Health (Larchmt); 2018 Mar; 27(3):231-237. PubMed ID: 29193980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
    Labrie F; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; BSc AB; Martel C; Vaillancourt M; Balser J; Moyneur É;
    Menopause; 2018 Nov; 25(11):1339-1353. PubMed ID: 30358731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
    Labrie F; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; Beauregard A; Martel C; Vaillancourt M; Balser J; Moyneur É;
    Menopause; 2016 Mar; 23(3):243-56. PubMed ID: 26731686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women.
    Kagan R; Williams RS; Pan K; Mirkin S; Pickar JH
    Menopause; 2010 Mar; 17(2):281-9. PubMed ID: 19779382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical effects of the fetal estrogen estetrol in a multiple-rising-dose study in postmenopausal women.
    Coelingh Bennink HJ; Verhoeven C; Zimmerman Y; Visser M; Foidart JM; Gemzell-Danielsson K
    Maturitas; 2016 Sep; 91():93-100. PubMed ID: 27451327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial.
    Archer DF; Goldstein SR; Simon JA; Waldbaum AS; Sussman SA; Altomare C; Zhu J; Yoshida Y; Schaffer S; Soulban G
    Menopause; 2019 Jan; 26(6):611-621. PubMed ID: 30694917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter, randomized study to select the minimum effective dose of estetrol (E4) in postmenopausal women (E4Relief): part 1. Vasomotor symptoms and overall safety.
    Gaspard U; Taziaux M; Mawet M; Jost M; Gordenne V; Coelingh Bennink HJT; Lobo RA; Utian WH; Foidart JM
    Menopause; 2020 Aug; 27(8):848-857. PubMed ID: 32379217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy.
    Bachmann G; Bobula J; Mirkin S
    Climacteric; 2010 Apr; 13(2):132-40. PubMed ID: 19863455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of a new vaginal gel for the treatment of symptoms associated with vulvovaginal atrophy in postmenopausal women: A double-blind randomized placebo-controlled study.
    De Seta F; Caruso S; Di Lorenzo G; Romano F; Mirandola M; Nappi RE
    Maturitas; 2021 May; 147():34-40. PubMed ID: 33832645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, multicenter, double-blind study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with dyspareunia as the most bothersome symptom.
    Kroll R; Archer DF; Lin Y; Sniukiene V; Liu JH
    Menopause; 2018 Feb; 25(2):133-138. PubMed ID: 28926514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between changes in vulvar-vaginal atrophy and changes in sexual functioning.
    Pinkerton JV; Bushmakin AG; Komm BS; Abraham L
    Maturitas; 2017 Jun; 100():57-63. PubMed ID: 28539177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.
    Portman D; Palacios S; Nappi RE; Mueck AO
    Maturitas; 2014 Jun; 78(2):91-8. PubMed ID: 24679891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study.
    Bachmann GA; Komi JO;
    Menopause; 2010; 17(3):480-6. PubMed ID: 20032798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized clinical trial comparing vaginal laser therapy to vaginal estrogen therapy in women with genitourinary syndrome of menopause: The VeLVET Trial.
    Paraiso MFR; Ferrando CA; Sokol ER; Rardin CR; Matthews CA; Karram MM; Iglesia CB
    Menopause; 2020 Jan; 27(1):50-56. PubMed ID: 31574047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TX-004HR clinically improves symptoms of vulvar and vaginal atrophy in postmenopausal women.
    Simon JA; Kagan R; Archer DF; Constantine GD; Bernick B; Graham S; Mirkin S
    Climacteric; 2019 Aug; 22(4):412-418. PubMed ID: 30862193
    [No Abstract]   [Full Text] [Related]  

  • 17. Menopause-specific quality of life across varying menopausal populations with conjugated estrogens/bazedoxifene.
    Abraham L; Pinkerton JV; Messig M; Ryan KA; Komm BS; Mirkin S
    Maturitas; 2014 Jul; 78(3):212-8. PubMed ID: 24837362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estradiol vaginal inserts (4 µg and 10 µg) for treating moderate to severe vulvar and vaginal atrophy: a review of phase 3 safety, efficacy and pharmacokinetic data.
    Constantine GD; Simon JA; Pickar JH; Archer DF; Bernick B; Graham S; Mirkin S
    Curr Med Res Opin; 2018 Dec; 34(12):2131-2136. PubMed ID: 30238814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled phase 2 pilot trial evaluating a novel, vaginal softgel capsule containing solubilized estradiol.
    Pickar JH; Amadio JM; Hill JM; Bernick BA; Mirkin S
    Menopause; 2016 May; 23(5):506-10. PubMed ID: 26836245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy.
    Constantine GD; Simon JA; Pickar JH; Archer DF; Kushner H; Bernick B; Gasper G; Graham S; Mirkin S;
    Menopause; 2017 Apr; 24(4):409-416. PubMed ID: 27922936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.